Abstract
While the majority of enzalutamide-treated patients with nonmetastatic castration-resistant prostate cancer in PROSPER had some increase from nadir in prostate-specific antigen at the time of radiographic progression, the median absolute increase was less than the Prostate Cancer Working Group 2 threshold of 2 ng/mL.
Original language | English |
---|---|
Pages (from-to) | 847-853 |
Number of pages | 7 |
Journal | European Urology |
Volume | 78 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Dec 2020 |
Externally published | Yes |
Keywords
- Enzalutamide
- Nonmetastatic castration-resistant prostate cancer
- Prostate Cancer Working Group 2
- Prostate-specific antigen progression